All News
Filter News
Found 808,615 articles
-
Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer
2/15/2022
Pulse Biosciences, Inc. today announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer.
-
Laurent Pharmaceuticals Starts Phase 3 Study With Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients
2/15/2022
Laurent Pharmaceuticals Inc. today announced that Luminis Health Research Institute in Annapolis MD, USA, has dosed the first patient in the Phase 3 expansion of the RESOLUTION Phase 2/3 clinical trial evaluating the efficacy of the novel COVID-19 oral antiviral LAU-7b.
-
renegade.bio Announces Partnership with Metabolomic Diagnostics to Reduce Pre-eclampsia-related Infant and Maternal Death
2/15/2022
Bay Area biotech firm renegade.bio today announced its partnership with Metabolomic Diagnostics, the Irish deep tech company specializing in the development of novel disease diagnostic solutions.
-
eXmoor Pharma appoints CTO as part of ambitious expansion strategy
2/15/2022
Lucy brings with her more than 10 years of industry experience focused on technology, process development and delivering large, complex projects.
-
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model
2/15/2022
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd generation non-hallucinogenic psychedelic analogs...
-
Trestle Biotherapeutics Announces License Agreement with Kumamoto University for Key Stem Cell Biology Technology for Regenerative Medicine
2/15/2022
Trestle Biotherapeutics today announced that it has entered into a license agreement with Kumamoto University.
-
InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica
2/15/2022
InMed Pharmaceuticals Inc. is pleased to announce the appointment of Gerard (Jerry) P. Griffin III as Vice President of Sales and Marketing at BayMedica, a wholly owned subsidiary of InMed.
-
Cytokinetics Announces Topline Results From METEORIC-HF
2/15/2022
Cytokinetics, Incorporated today announced topline results from METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv MecarbilRelated to Increased Contractility in Heart Failure), a Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure
-
Kairos Pharma Announces FDA Clearance of Investigational New Drug (IND) for ENV105 for the Treatment of Prostate Cancer
2/15/2022
Kairos Pharma, Ltd. ("Kairos"), a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, today announced that it has received FDA approval to proceed with a Phase 2 clinical trial of ENV105 with apalutamide for the treatment of metastatic castration-resistant prostate cancer.
-
Quipt Home Medical Reports Record First Quarter Fiscal 2022 Financial Results
2/15/2022
Quipt Home Medical Corp. today announced its first quarter fiscal 2022 financial results and operational highlights.
-
Inflammatory Response Research Announces Positive Data from Phase 1 Pilot Study of IRR-401 in COVID Patients
2/15/2022
Inflammatory Response Research, Inc. (“IRR”), a drug development company focused on pharmaceutical products for the treatment of inflammatory disorders and conditions, today announced positive data from a Phase 1 Pilot Study of IRR-401 in COVID-19 (+) patients.
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2/15/2022
TG Therapeutics, Inc. today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS).
-
Theradaptive Wins Additional FDA Breakthrough Designation for Spinal Fusion
2/15/2022
Theradaptive, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for its OsteoAdapt SP Spinal Fusion implant indicated for posterolateral spinal fusion to treat degenerative disc disease, spondylolisthesis, or retrolisthesis.
-
Opus Genetics Appoints Brian Leising Vice President, Manufacturing
2/15/2022
Opus Genetics today announced the appointment of Brian Leising as Vice President of Manufacturing.
-
Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn®
2/15/2022
Brainstorm Cell Therapeutics Inc. today announced that the Brazilian Patent Office has granted the patent application.
-
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
2/15/2022
Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational natural killer (NK) cell therapy, CYNK-101, for treatment of gastric/gastroesophageal junction cancer.
-
Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial
2/15/2022
Stealth BioTherapeutics Corp announced today that the final patient in its 176-subject, ReCLAIM-2 phase 2 clinical trial for extra-foveal geographic atrophy associated with dry age-related macular degeneration (AMD) has completed treatment.
-
HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV
2/15/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), today announced it has entered into an amended and restated collaboration and license agreement with Gilead to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV).
-
Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
2/15/2022
Palatin Technologies, Inc. today announced results for its fiscal second quarter ended December 31, 2021.
-
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
2/15/2022
Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.